Stapled anoplin peptide combined with photothermal therapy enhances oncolytic immunotherapy of triple-negative breast cancer.
10.19540/j.cnki.cjcmm.20230510.302
- Author:
Wei-Dong GAO
1
;
Xiao-Xia LIU
1
;
Ting YANG
1
;
Jia-Yi LIN
1
;
Yu-Xuan SONG
1
;
Sheng-Xin LU
1
;
Xiao-Kun ZHANG
1
;
Ye WU
1
;
Xin LUAN
1
;
Wei-Dong ZHANG
2
Author Information
1. Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
2. Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China School of Pharmacy, Naval Medical University (Second Military Medical University) Shanghai 200433, China.
- Publication Type:Journal Article
- Keywords:
anoplin;
immunogenic cell death;
oncolytic immunotherapy;
photothermal therapy;
triple-negative breast cancer
- MeSH:
Humans;
Animals;
Mice;
Photothermal Therapy;
Triple Negative Breast Neoplasms/pathology*;
Antimicrobial Cationic Peptides;
Immunotherapy/methods*;
Cell Line, Tumor;
Phototherapy/methods*;
Nanoparticles/chemistry*
- From:
China Journal of Chinese Materia Medica
2023;48(18):4981-4992
- CountryChina
- Language:Chinese
-
Abstract:
This study constructed a nano-drug delivery system, A3@GMH, by co-delivering the stapled anoplin peptide(Ano-3, A3) with the light-harvesting material graphene oxide(GO), and evaluated its oncolytic immunotherapy effect on triple-negative breast cancer(TNBC). A3@GMH was prepared using an emulsion template method and its physicochemical properties were characterized. The in vivo and in vitro photothermal conversion abilities of A3@GMH were investigated using an infrared thermal imager. The oncoly-tic activity of A3@GMH against TNBC 4T1 cells was evaluated through cell counting kit-8(CCK-8), lactate dehydrogenase(LDH) release, live/dead cell staining, and super-resolution microscopy. The targeting properties of A3@GMH on 4T1 cells were assessed using a high-content imaging system and flow cytometry. In vitro and in vivo studies were conducted to investigate the antitumor mechanism of A3@GMH in combination with photothermal therapy(PTT) through inducing immunogenic cell death(ICD) in 4T1 cells. The results showed that the prepared A3@GMH exhibited distinct mesoporous and coated structures with an average particle size of(308.9±7.5) nm and a surface potential of(-6.79±0.58) mV. The encapsulation efficiency and drug loading of A3 were 23.9%±0.6% and 20.5%±0.5%, respectively. A3@GMH demonstrated excellent photothermal conversion ability and biological safety. A3@GMH actively mediated oncolytic features such as 4T1 cell lysis and LDH release, as well as ICD effects, and showed enhanced in vitro antitumor activity when combined with PTT. In vivo, A3@GMH efficiently induced ICD effects with two rounds of PTT, activated the host's antitumor immune response, and effectively suppressed tumor growth in 4T1 tumor-bearing mice, achieving an 88.9% tumor inhibition rate with no apparent toxic side effects. This study suggests that the combination of stapled anoplin peptide and PTT significantly enhances the oncolytic immunotherapy for TNBC and provides a basis for the innovative application of anti-tumor peptides derived from TCM in TNBC treatment.
